For example, a preclinical bladder cancer study of intratumoral agonist CD40 mAb showed anti‐tumor efficacy with reduced toxicity compared to systemic administration, which yielded high liver accumulation.[17] A phase I clinical study evaluated intratumoral delivery of humanized IgG1 agonist CD40, ADC‐1013 in various solid tumors. Here, CD40 is linked to urinary bladder carcinoma.